newsfilter
← Latest News
GlobeNewswire·

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

RADX
  • Radiopharm Theranostics Limited entered a Securities Purchase Agreement to issue 1,281,646 ADSs at US$3.16 per share in a registered direct offering, raising approximately US$4.1 million gross.
  • Concurrently, the company issued unregistered warrants to purchase up to 1,281,646 ADSs with an exercise price of US$3.79 per ADS, expiring July 31, 2029.
  • H.C. Wainwright & Co. acts as the exclusive U.S. placement agent, with the offering expected to close around July 28, 2026.
  • The U.S. ADS issuance utilizes a shelf registration statement on Form F-3 effective December 23, 2025, while the warrants were issued under Section 4(a)(2) of the Securities Act.
  • In Australia, the company secured firm commitments for a private placement of approximately A$6.7 million (US$4.7 million), with 40.0 million shares requiring shareholder approval due to ASX listing limits.
  • A Share Purchase Plan for Australian & New Zealand shareholders aims to raise up to A$6 million (US$4.2 million) and is also subject to shareholder approval.
  • Subscribers under the Australian Placement & Share Purchase Plan will receive one option for every new share, exercisable at A$0.018 per option, expiring July 31, 2029.
  • Shareholder approval for the Australian Placement, Share Purchase Plan, & warrant issuances is sought at an extraordinary general meeting scheduled for September 11, 2026.
  • Proceeds from all offerings will fund the RAD101 registrational study, clinical milestones, strategic partnerships, & working capital.
  • The press release states U.S. shareholders cannot participate in the Share Purchase Plan, & Australian securities are not registered under the U.S. Securities Act.